Latest news
Stay updated with our latest insights and breakthroughs
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Press releases
ÃÛÌÒTV Therapeutics doses first participants with axSpA in novel ERAP1 inhibitor trial

Press releases
ÃÛÌÒTV Therapeutics doses first participants with axSpA in novel ERAP1 inhibitor trial

Feature
A dark horse: The untapped therapeutic potential of ERAP2

Feature
A dark horse: The untapped therapeutic potential of ERAP2

Press releases
ÃÛÌÒTV Therapeutics appoints Edwin Moses as Chair

Press releases
ÃÛÌÒTV Therapeutics appoints Edwin Moses as Chair

In the media
WATCH: Targeting disease at the source

In the media
WATCH: Targeting disease at the source

Press releases
ÃÛÌÒTV Therapeutics begins dosing of the first ÃÛÌÒTV to target the antigenic source of autoimmunity

Press releases
ÃÛÌÒTV Therapeutics begins dosing of the first ÃÛÌÒTV to target the antigenic source of autoimmunity

Feature
Could antigen modulation address autoimmune diseases?

Feature
Could antigen modulation address autoimmune diseases?

Press releases
ÃÛÌÒTV Therapeutics presents first clinical data for GRWD5769, a first-in-class ERAP1 Inhibitor, at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting

Press releases
ÃÛÌÒTV Therapeutics presents first clinical data for GRWD5769, a first-in-class ERAP1 Inhibitor, at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting

Press releases
ÃÛÌÒTV Therapeutics to Present First Clinical Data for GRWD5769, a First-in-Class ERAP1 Inhibitor, at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting

Press releases
ÃÛÌÒTV Therapeutics to Present First Clinical Data for GRWD5769, a First-in-Class ERAP1 Inhibitor, at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting

Press releases
ÃÛÌÒTV Therapeutics closes oversubscribed $50m Series B financing expansion, led by ICG Life Sciences Team, to accelerate and expand first-of-its-kind antigen modulation technology

Press releases
ÃÛÌÒTV Therapeutics closes oversubscribed $50m Series B financing expansion, led by ICG Life Sciences Team, to accelerate and expand first-of-its-kind antigen modulation technology

Press releases
Promising preclinical data reported at AACR 2023

Press releases
Promising preclinical data reported at AACR 2023

Press releases
Announcing the dosing of first patient in our clinical study

Press releases
Announcing the dosing of first patient in our clinical study

Press releases
$49 Million Series B financing oversubscribed

Press releases
$49 Million Series B financing oversubscribed

Press releases
Supply agreement with Regeneron for GRWD5769 clinical trial

Press releases
Supply agreement with Regeneron for GRWD5769 clinical trial

Press releases
Brett Carter joins board of Directors of Australian subsidiary

Press releases
Brett Carter joins board of Directors of Australian subsidiary

Press releases
Formation of our Clinical Advisory Board

Press releases















